• Patients’ recall of response to past depression treatments agrees poorly with standardized outcome questionnaires they completed at the time of treatment.
• Recall of treatment response is fair for the preceding 6 months and poor for treatments earlier than the last 6 months.
• Accurate assessment of past treatment response will probably require review of medical records.

[Close]

• Depression is common in patients seeking treatment for anxiety disorders, and depressed patients often present with more severe anxiety symptoms and other clinical complexities.
• Depression does not, however, compromise the effectiveness of standard treatments for anxiety disorders; on the contrary, substantial reductions in anxiety symptoms and disability were observed in depressed patients receiving treatment for anxiety disorders.
• Empirically supported treatments for anxiety (cognitive-behavioral therapy, medication management, or their combination) should typically be offered to patients with co-occurring depression.

[Close]

• Adult attention-deficit/hyperactivity disorder (ADHD) is a common and highly impairing condition.
• A novel nonstimulant medication would be helpful in the treatment of adults with ADHD.
• The findings of this trial indicate that metadoxine ER is a well-tolerated and effective treatment for adults with ADHD.

[Close]

• Asenapine is an approved treatment for schizophrenia in the United States.
• The reported meta-analyses indicate that the efficacy of asenapine for acute schizophrenia is superior to placebo and comparable to several other second-generation antipsychotics.

[Close]

• Self-reported screening for bipolar disorder using the Mood Disorder Questionnaire (MDQ) may often yield false-positive results in patients with mood symptoms and substance misuse—particularly those with lifetime misuse of multiple substances.
• Adapting the MDQ to an interview format enables clinicians to probe and clarify patients’ affirmative item endorsements, in turn substantially increasing the likelihood for identifying true cases of bipolar disorder.
• In mood-disordered patients with substance misuse, negative self-report MDQ screens suggest the absence of bipolar disorder with relatively high confidence.

[Close]

• Men hospitalized for treatment of BPSD were more likely than women to present with aggressiveness and less likely to present with paranoid, delusional ideation; hallucination; affective disturbances; and anxieties and phobias.
• Men with BPSD were less likely than women to be discharged into their communities.
• More effective treatment options for aggressiveness and enhanced care strategies may be required for men.

[Close]

• Clinicians should consider the volume of white matter hyperintensities (WMHs), which seem to be predominantly associated with frontal/executive dysfunction irrespective of the presence of the apolipoprotein E (APOE) ε4 allele, in the elderly.
• On the other hand, APOE ε4 carriers perform worse on memory tests, and it is only APOE ε4 noncarriers that show some relationship between WMH severity and memory performance among the elderly.
• Current evidence supports the disassociation of APOE and WMHs relative to cognitive performance, a finding that may be helpful for clinicians in predicting the characteristics of cognitive impairment as affected by the APOE ε4 allele or WMHs.

[Close]